SynthesisOrphanet journal of rare diseases2025
Safety and efficacy of umbilical cord-derived stem cell therapy for the treatment of cerebral palsy patients: a systematic review.
Synthesis in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAllogeneic umbilical cord blood is regarded as a beneficial source of stem cells with varying therapeutic potential. On the other hand, cerebral palsy is one of the neurological conditions that are the primary contributor to early childhood disability. The aim of this systematic review was to harvest data from currently available sources to determine the safety and efficacy of treating cerebral palsy patients with stem cells obtained from allogeneic umbilical cords.
methodsFor this study, systematic searches of the databases PubMed, Scopus, Web of Science, Embase, ScienceDirect, and Google Scholar were conducted with no time Limit until November 2022. Duplicates were found and eliminated after entering the data from the chosen studies into the Endnote reference management program. The remaining studies were assessed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses phases and the inclusion and exclusion criteria (PRISMA). The search was performed using the keywords of Safety, Effectiveness, Stem Cells, Cerebral Palsy, and Umbilical and the (AND) and (OR) operators and their combinations were used to construct the search strategies.
resultsAfter several assessments and based on the inclusion and exclusion criteria, 31 of the remaining 58 studies were eliminated. The systematic review method included 7 final studies in the end. Based on the reviewed studies, it was reported that umbilical cord blood is currently one of the best sources of adult stem cells that contain cells with a wide range of therapeutic potential. These studies report that allogeneic umbilical cord blood has the potential to treat cerebral palsy and that concomitant administration of recombinant human erythropoietin (EPO), which has neurotrophic properties, may enhance the efficacy of umbilical cord blood. These studies state that pneumonia and irritability have been reported as complications of umbilical cord blood transfusion. These studies reported that administration of stem cells significantly improves motor function. The safety and efficacy of treating cerebral palsy patients with stem cells taken from an allogeneic umbilical cord were reported in all included investigations.
conclusionCerebral palsy has negative consequences on patients' quality of life, many aspects of the treatment based on allogeneic umbilical cord stem cells remain unknown. Therefore, the optimal dose, the most suitable type of cell, cell identification, and the best administration route should be determined appropriately. The quality of life of patients with cerebral palsy may be negatively impacted, and many details of the allogeneic umbilical cord stem cell therapy are yet unknown. Consequently, it is important to discover the most suitable type of cell, the optimal dose, and the best delivery method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.